

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA AR101 for peanut allergy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Issue raised at consultation

Ethnicity: A comment from the patient group noted the lack of research on the impact of allergy on different ethnic groups, there is currently a working group addressing the subject at BSACI.

Issues raised at TC during scoping

Access to specialist centre: at the TC with clinicians and company during scoping, the issue of geographical access to treatment and variations in capacity issues within specialist allergy clinics was discussed.

Age: stakeholders noted that there is a need for treatment among adults but this treatment targets children aged 4 to 17, this is likely an equality issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Ethnicity: Currently unknown impact on different ethnicities but if recommended, the recommendation would apply equally regardless of ethnicity, so a difference in disease prevalence does not in itself represent an equality issue.

Access to specialist centres: an implementation and equity issue, not an equality issue to be considered by any committee recommendations.

Age: AR101 can only be appraised within its MA so it does not constitute an equality issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

N/A

Approved by Associate Director (name): Nicole Elliott

Date: 4/03/2021